# Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.

> **NCT03453112** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 494 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Foster 100/6mg NEXThaler
- **DRUG:** Foster 100/6mg pMDI

## Key facts

- **NCT ID:** NCT03453112
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2021-12-28
- **Final completion:** 2021-12-28
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03453112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03453112, "Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03453112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*